<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653521</url>
  </required_header>
  <id_info>
    <org_study_id>M201505</org_study_id>
    <nct_id>NCT02653521</nct_id>
  </id_info>
  <brief_title>The Clinical Physics Research of Image Guided Adaptive Radiation Therapy for Esophagus Cancer</brief_title>
  <official_title>The Clinical Physics Research of Image Guided Adaptive Radiation Therapy for Esophagus Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the benefit of adaptive radiation therapy (adaptive
      radiation therapy, ART) for esophageal cancer, using dose tracking technique with online
      images and deformable registration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of study is to evaluate the benefit of adaptive radiation therapy(ART) for esophageal
      cancer. 80 patients with locally advanced esophageal cancer will be treated with 3D-CRT(three
      dimensional conformal radiotherapy, 3D-CRT)/IMRT(intensity modulated radiotherapy, IMRT),
      dividing to experimental group and control group (40 patients each). All patients are
      kVCT(kilo-voltage computed tomography, kVCT) scanned weekly(the fifth fraction in a week) and
      CBCT (cone beam computed tomography, CBCT) scanned per fraction before treatment. Irradiated
      dose distribution of each patient is calculated using the CBCT images corrected with
      validated modelling and accumulate the volumetric dose for all PTV(planning target
      volume,PTV) and OARs(organs at risk, OAR) using deformable registration algorithm. For the
      experimental group, replan the treatment when the target volume is not covered by the
      prescribed dose or OARs is overdose beyond the action level to achieve an optimal dose
      distribution. Conversely, no action is taken in the control group and the original plan will
      be used for the full treatment course. Dosimetric parameters (such as the ratio of target
      coverage, the mean dose of OARs, etc) ,treatment toxicities (such as radiation pneumonitis
      and esophagitis), PFS（Progress Free Survival,PFS）and OS（Overall Survival, OS）of the two
      groups will be analyzed and compared in the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 30, 2015</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity of treatment</measure>
    <time_frame>One year</time_frame>
    <description>Evaluating the treatment toxicity weekly during treatment course and at the time of one year after treatment according to the NCI CTCAE 4.0 (The National Cancer Institute Common Terminology Criteria for Adverse Events,NCI-CTCAE, Version 4.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress Free Survival(PFS）</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.</time_frame>
    <description>the length of time during and after the treatment of a disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival（OS）</measure>
    <time_frame>2 years</time_frame>
    <description>The survival time from the start of treatment to death or the time of the last follow-up of this study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dosimetric Parameters</measure>
    <time_frame>Six weeks</time_frame>
    <description>Accumulated dose distribution of the full treatment course.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>adaptive radiation therapy (ART)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 patients treated with ART, using dose adaptation method to match the change of PTV and movement of OARs and achieve an optimal dose distribution using online CBCT images.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>40 patients treated with original plan for full treatment course.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Dose adaptation</intervention_name>
    <description>Replanning the treatment to adapt the change of PTV and movement of OARs to achieve an optimal dose distribution using online CBCT images.</description>
    <arm_group_label>adaptive radiation therapy (ART)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with locally advanced esophageal cancer

          -  ECOG(Eastern Cooperative Oncology Group, ECOG) physical status score：0-2

          -  Charlson complications index score≤4

          -  First second forced expiratory volume ≥1 liter

          -  Patients and their families agreed and signed the informed consent

        Exclusion Criteria:

          -  Previous treatment with other malignant tumor

          -  Had anti-tumor treatment, including (chemotherapy, radiotherapy, surgery)

          -  Any taboo disease or condition of radiotherapy and chemotherapy

          -  With malignant pleural effusion and pericardial effusion

          -  Participated to other clinical test within 30 days before this experiment

          -  With uncontrolled seizures or loss of mental self-control

          -  Drug takers, chronic alcoholism, and HIV/AIDS patients

          -  Has a history of severe allergic or specific physique

          -  Researchers think that is unfavorable to the test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deng Xiaowu, PHD.</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liu Hui, PHD.</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peng Yinglin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiu Bo, PHD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu Hui, PHD.</last_name>
    <phone>+86 020-8734-3031</phone>
    <email>liuhui@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiu Bo, PHD.</last_name>
    <phone>+86 020-8734-3031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deng Xiaowu, PHD</last_name>
      <phone>+86 020-8734-3036</phone>
      <email>dengxw@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Liu Hui, PHD</last_name>
      <phone>+86 020-8734-3031</phone>
      <email>luihui@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Peng Yinglin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hawkins MA, Brooks C, Hansen VN, Aitken A, Tait DM. Cone beam computed tomography-derived adaptive radiotherapy for radical treatment of esophageal cancer. Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):378-83. doi: 10.1016/j.ijrobp.2009.05.045. Epub 2009 Sep 21.</citation>
    <PMID>19775828</PMID>
  </reference>
  <reference>
    <citation>Sriram P, Syamkumar SA, Kumar JS, Prabakar S, Dhanabalan R, Vivekanandan N. Adaptive volumetric modulated arc treatment planning for esophageal cancers using cone beam computed tomography. Phys Med. 2012 Oct;28(4):327-32. doi: 10.1016/j.ejmp.2011.10.006. Epub 2011 Nov 10.</citation>
    <PMID>22079402</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2015</study_first_submitted>
  <study_first_submitted_qc>January 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Deng Xiaowu</investigator_full_name>
    <investigator_title>Director of radiotherapy department</investigator_title>
  </responsible_party>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Adaptive Radiation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

